Inquiry Basket
Loading ......
Carbohydrate antigen 242, abbreviated CA 242, is a sialylated carbohydrate tumor marker that has occupied a quiet but durable niche in the serological work-up of digestive tract cancers for nearly four decades. First characterized in the mid-1980s through monoclonal antibodies raised against a human colorectal carcinoma cell line, CA 242 belongs to the family of mucin-associated carbohydrate antigens that also includes CA 19-9 and CA 50. What distinguishes CA 242 from its better-known relatives is not a completely separate chemical identity but a subtly different epitope and, crucially, a more favorable specificity profile in the presence of benign biliary and pancreatic disease. As colorectal, pancreatic, and biliary tract cancers continue to impose a heavy global burden — and as early detection remains the single strongest lever on survival — CA 242 deserves renewed attention. This review surveys the biochemistry of CA 242, its performance in pancreatic and colorectal cancer, its relationship to CA 19-9 and carcinoembryonic antigen (CEA), its emerging role in other gastrointestinal malignancies, and the directions most likely to shape its future clinical use.
CA 242 is not a protein in the conventional sense but a carbohydrate epitope displayed on mucin-type glycoproteins and glycolipids at the cell surface. Structurally, it is a sialylated carbohydrate structure related to, but not identical with, the Lewis-type determinants that define CA 19-9 (sialyl-Lewis a) and CA 50. Although CA 242 shares the sialylated Lewis backbone with these markers, the precise conformation recognized by its cognate monoclonal antibody differs, which accounts for both partial co-expression and the clinically important differences in specificity. The biosynthesis of CA 242 is governed by the same glycosylation machinery that builds Lewis antigens, yet its final epitope depends on additional sialylation and chain-extension steps, which explains why the marker is not simply a surrogate for CA 19-9 and why Lewis-negative individuals can still express it in some contexts. In healthy tissue, CA 242 is barely detectable: it is expressed at low levels in the columnar and goblet cells of the colon and in the epithelia of the bile and pancreatic ducts, but circulating concentrations are normally very low. Malignant transformation in the pancreas, colorectum, stomach, and biliary tree is associated with re-expression and shedding of mucin-bound CA 242 into the bloodstream, where it can be captured by immunoassay. The marker's utility rests on this on–off contrast between normal physiology and cancer, amplified by its relative resistance to the false-positive elevations that plague CA 19-9 when bile flow is obstructed.
Figure 1. The median serum concentrations of CA19-9 and CA242 in controls and patients with CRC.
(Source: Yang XQ, et al. 2012)
Pancreatic cancer is the setting in which CA 242 is most firmly established, and it is here that its specificity advantage is most clinically relevant. CA 19-9 is the guideline-endorsed serological marker for pancreatic adenocarcinoma, yet it is well known to produce false-positive elevations in benign biliary obstruction, cholangitis, hepatitis, and other non-malignant hepatobiliary conditions, and it can be falsely negative in patients who are Lewis antigen-negative. CA 242, by contrast, is far less perturbed by cholestasis and biliary epithelial injury, meaning that an elevated CA 242 in a jaundiced patient carries stronger positive weight than an elevated CA 19-9. Studies consistently report that CA 242 performs comparably to CA 19-9 in raw sensitivity and specificity for pancreatic cancer, while offering superior discrimination when benign hepatobiliary disease must be excluded. In advanced disease, CA 242 has also shown value as a prognostic indicator: in one investigation of pancreatic cancer with liver metastasis, elevated CA 242 contributed to a multi-marker panel that improved prediction of metastatic spread and survival, and circulating CA 242 levels tracked with adverse outcomes. The practical lesson is that CA 242 and CA 19-9 are best used together, the former compensating for the latter's vulnerability to benign biliary noise.
In colorectal cancer, CA 242 functions primarily as a complement to CEA, the traditional colorectal marker. CEA is sensitive to tumor burden but lacks organ specificity and is influenced by smoking and benign inflammation; CA 242 adds a layer of gastrointestinal specificity. The two markers are largely independent, and their combined use raises diagnostic sensitivity for colorectal cancer well above either alone. CA 242 also correlates withclinicopathological features such as tumor location, TNM stage, depth of invasion, and the presence of lymph node or distant metastasis, making it informative not only for detection but for characterizing disease extent at presentation. Recent evidence has extended CA 242's role from diagnosis into fine-grained prognosis. A large retrospective longitudinal cohort demonstrated that the perioperative trajectory of CA 242 — not merely its single preoperative value — independently predicts recurrence-free survival: patients whose CA 242 normalized after surgery fared far better than those with persistently elevated levels, and the postoperative-to-preoperative CA 242 ratio further stratified recurrence risk. These longitudinal, trajectory-based analyses represent a methodological advance, shifting the field from static single-timepoint thresholds toward dynamic monitoring that captures the biology of residual or recurrent disease. In systematic evaluation, pooled analyses of Chinese populations indicate that while CEA, CA 19-9, and CA 242 each have modest individual accuracy for colorectal cancer screening, their combination lifts overall diagnostic performance substantially, albeit with some specificity trade-off, and combined detection has also been linked to better characterization of chemotherapy tolerance and adverse events.
Figure 2. -Log10 p values for CA242 in 27 different types of diseases compared to that of healthy controls.
(Source: Dou H, et al. 2019)
The strategic question for any laboratory is not whether CA 242 is "better" than CA 19-9 or CEA in isolation, but how the three combine. CA 19-9 remains the most sensitive single marker for pancreatic adenocarcinoma and the only one embedded in major guidelines, but its specificity is compromised by hepatobiliary benign disease and its sensitivity lost in Lewis-negative individuals who lack the fucosyltransferase required to synthesize the epitope. CEA is the cornerstone colorectal marker but is organ-non-specific and affected by smoking and benign inflammation. CA 242 slots into this landscape as a high-specificity, gastrointestinal-leaning antigen whose main strength is confirming malignancy when CA 19-9 is ambiguously elevated by benign causes, and adding sensitivity when paired with CEA in colorectal disease. Because CA 242's epitope is generated by somewhat different glycosylation steps, it can remain informative in some patients where CA 19-9 is falsely negative, although it is not a complete solution to the Lewis-negative problem. The evidence base converges on a clear recommendation: single-marker testing is inferior to multi-marker panels, and CA 242 is a valuable panel member rather than a stand-alone replacement. Importantly, none of these markers should be interpreted without imaging and clinical context, and all are tools for supporting — not substituting — histological and radiological diagnosis. The choice of panel should also be anatomy-driven: CA 19-9 plus CA 242 for pancreaticobiliary suspicion, CEA plus CA 242 for colorectal evaluation, with the combination logic dictated by which benign mimics are most likely to confuse the picture.
Beyond pancreas and colorectum, CA 242 has been studied across the spectrum of digestive malignancies. In biliary tract cancer, notably hilar cholangiocarcinoma, elevated preoperative CA 242 has been linked to worse overall and relapse-free survival, with vascular invasion and lymph node metastasis mediating the association — suggesting CA 242 as a prognostic marker that reflects the tumor's invasive phenotype rather than merely its bulk. In gastric cancer, CA 242 is frequently included in multi-marker panels alongside CEA, CA 19-9, and CA 72-4, where it contributes to discrimination between malignant and benign gastric disease, although its standalone value is tempered by the heterogeneity of gastric carcinogenesis and the influence of intestinal metaplasia, a premalignant condition that can itself raise carbohydrate antigen levels. CA 242 has also been reported in hepatobiliary and other adenocarcinomas, reinforcing its identity as a broadly expressed epithelial carbohydrate marker of glandular malignancy. A consistent theme is that CA 242's incremental value is greatest in combination with other markers and in anatomical sites where benign inflammatory mimics would otherwise cloud interpretation, and that its relative indifference to cholestasis makes it especially useful precisely where CA 19-9 is most unreliable.
The future of CA 242 lies less in discovery than in smarter integration. First, harmonization of assay platforms and reference intervals remains essential; variability between methods has historically complicated cross-study comparison and clinical threshold-setting, and the lack of universally agreed cut-offs is a genuine barrier to multicenter adoption. Method standardization, possibly through reference materials and external quality assessment schemes, would allow the promising single-center findings described above to be pooled and validated at scale. Second, the trajectory-based prognostic paradigm demonstrated in colorectal cancer should be extended and validated prospectively, potentially turning routine postoperative CA 242 monitoring into a tool for risk-adapted surveillance in which patients with unfavorable CA 242 kinetics are followed more intensely. Third, multi-analyte algorithms that fuse CA 242 with CEA, CA 19-9, and emerging molecular markers — possibly augmented by machine learning — are the most promising route to the early detection that currently eludes digestive tract cancers, where no single blood test performs well enough alone. Finally, CA 242's specificity advantage in cholestatic patients makes it a natural candidate for combination strategies that reduce the false-positive cascade triggered by benign biliary disease, and its inclusion in next-generation multivariate indices is therefore logically compelling. As liquid biopsy and multivariate diagnostics mature, CA 242's role is likely to endure not as a lone sentinel but as a dependable, specificity-rich component of the diagnostic panel — a quiet workhorse whose value is multiplied by the company it keeps.
References
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| CA 242 | DEIA1999 | Human ca242(cancer antigen 242) ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates and other biological fluids | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| CA 242 | DMABRM095T | Mouse Anti-Human CA 242 monoclonal antibody, clone 3D3 | Mouse | IgG1 | ELISA(Cap) | Inquiry |
| DMABRM096T | Mouse Anti-Human CA 242 monoclonal antibody, clone 2C2 | Mouse | IgG1 | ELISA(Det) | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| CA 242 | DAG-T1009 | Human CA 242 | N/A | Unconjugated | N/A | Inquiry |
| DAGA-800 | CA 242 from Metastatic liver (Immunogen grade) | Metastatic liver | Unconjugated | Immunogen, Controls | Inquiry |
Loading ......
